Short answer
CorMedix Inc. (CRMD) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Heron asset acquisition for $145.0M cash plus 14,583,333 CRMD shares, expanding CorMedix’s commercial pharmaceutical portfolio.
CorMedix Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Heron asset acquisition for $145.0M cash plus 14,583,333 CRMD shares, expanding CorMedix’s commercial pharmaceutical portfolio
- Additional contingent consideration: 5.0% royalties above $25.0M annual sales, plus up to $55.0M ZYNRELEF earn-outs
- Acquisition financing: senior secured facility up to $150.0M, including $75.0M Tranche A for transaction funding
- Debt carries three-month Term SOFR plus 5.75%, with a 3.50% floor, 1.5% upfront consideration and fifth-anniversary maturity
- Closing requires Heron stockholder approval and regulatory conditions, with a six-month outside date and $4.0M seller termination fee risk
Item 2.03 · Creation of a Direct Financial Obligation
- Loan Agreement creates a direct financial obligation for CorMedix
- Item 1.01 contains the operative borrowing terms and should be reviewed for amount, interest rate, maturity and covenants
Item 3.02 · Unregistered Sales of Equity Securities
- CorMedix will issue unregistered common shares as acquisition consideration and potentially for earn-out payments
- Share issuance relies on the Securities Act Section 4(a)(2) private-placement exemption
- Potential dilution depends on the Stock Consideration and earn-out terms in Item 1.01
- Earn-out shares create additional dilution if specified performance conditions are met
Item 7.01 · Regulation FD Disclosure
- November 9, 2026 press release announces CorMedix’s proposed purchase of substantially all Heron assets
- Transaction includes four FDA-approved commercial brands, potentially broadening CorMedix’s revenue base and product portfolio
- Closing requires Heron stockholder approval, regulatory clearances and other customary conditions
- CorMedix expects synergies and earnings accretion, but integration, reimbursement and market-acceptance risks remain material
- Consideration includes privately placed CorMedix shares, creating potential dilution for existing shareholders
Item EX-99.1 · Exhibit EX-99.1
- Acquisition adds four commercial products and approximately $150 million in trailing-twelve-month revenue to CorMedix’s institutional-care platform
- Upfront consideration: $145 million cash plus 14,583,333 CorMedix shares, valued at approximately $77.6 million using November 6’s $5.32 price
- Potential additional payments: up to $55 million tied to 2028 ZYNRELEF sales, plus 5% royalties above specified sales thresholds
- Management projects $45-$60 million annual operating-cost synergies by year-end 2027 and immediate earnings and free-cash-flow accretion
- Financing includes a $75 million draw under a new $150 million Pharmakon term facility, with closing targeted for the first quarter of 2027 after approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CorMedix Inc. 8-K filings
Get the next CRMD 8-K as it lands
Follow CRMD for push alerts, or ask the research agent what this filing means.